Cargando…
Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis
Patient Acceptable Symptom State (PASS) is an absolute threshold proposed for symptomatic variables in osteoarthritis (OA) to determine the point beyond which patients consider themselves well and, as such, are satisfied with treatment. Two large previously reported studies of knee OA have shown tha...
Autores principales: | Dougados, Maxime, Moore, Alan, Yu, Shaohua, Gitton, Xavier |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860070/ https://www.ncbi.nlm.nih.gov/pubmed/17266764 http://dx.doi.org/10.1186/ar2118 |
Ejemplares similares
-
Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison
por: Stam, WB, et al.
Publicado: (2012) -
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]
por: Wittenberg, Ralf H, et al.
Publicado: (2006) -
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
por: Stricker, Kirstin, et al.
Publicado: (2008) -
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
por: Profit, Louise, et al.
Publicado: (2007) -
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis
por: Mackenzie, Isla S., et al.
Publicado: (2012)